{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:07Z","timestamp":1788998407090,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Contracept Reprod Med"],"DOI":"10.1186\/s40834-025-00353-8","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T04:52:41Z","timestamp":1741927961000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Population characteristics of intrauterine device users in real-world clinical practice across Europe \u2013 insights from the EURAS-LCS12 study"],"prefix":"10.1186","volume":"10","author":[{"given":"Lisa","family":"Eggebrecht","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Bauerfeind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Boehnke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Hagemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mareike","family":"Viet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Pauls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"von Stockum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz","family":"Klinghardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaas","family":"Heinemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,14]]},"reference":[{"key":"353_CR1","unstructured":"UN. Population division. Contraceptive use by method 2019. UN; 2019."},{"key":"353_CR2","doi-asserted-by":"publisher","first-page":"589","DOI":"10.2147\/IJWH.S99705","volume":"8","author":"DJ Costescu","year":"2016","unstructured":"Costescu DJ. Levonorgestrel-releasing intrauterine systems for long-acting contraception: current perspectives, safety, and patient counseling. Int J Womens Health. 2016;8:589\u201398. https:\/\/doi.org\/10.2147\/IJWH.S99705.","journal-title":"Int J Womens Health"},{"key":"353_CR3","unstructured":"Bayer HealthCare Pharmaceuticals Inc. Mirena\u00ae Prescribing Information. 2000."},{"key":"353_CR4","unstructured":"Bayer HealthCare Pharmaceuticals Inc. Kyleena\u00ae Prescribing Information. 2016."},{"key":"353_CR5","unstructured":"Bayer HealthCare Pharmaceuticals Inc. Skyla\u00ae Prescribing Information. 2013."},{"issue":"3","key":"353_CR6","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.fertnstert.2011.12.003","volume":"97","author":"K Gemzell-Danielsson","year":"2012","unstructured":"Gemzell-Danielsson K, Schellschmidt I, Apter D. A randomized, phase II study describing the efficacy, bleeding profile, and safety of two low-dose levonorgestrel-releasing intrauterine contraceptive systems and Mirena. Fertil Steril. 2012;97(3):616\u201322. https:\/\/doi.org\/10.1016\/j.fertnstert.2011.12.003..e1-3.","journal-title":"Fertil Steril"},{"issue":"6","key":"353_CR7","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1097\/AOG.0000000000000019","volume":"122","author":"A Nelson","year":"2013","unstructured":"Nelson A, Apter D, Hauck B, Schmelter T, Rybowski S, Rosen K, et al. Two low-dose levonorgestrel intrauterine contraceptive systems: a randomized controlled trial. Obstet Gynecol. 2013;122(6):1205\u201313. https:\/\/doi.org\/10.1097\/AOG.0000000000000019.","journal-title":"Obstet Gynecol"},{"key":"353_CR8","unstructured":"Bayer HealthCare Pharmaceuticals Inc. Cost of unintended pregnancy: model technical report\u2014UK. 2012."},{"issue":"4","key":"353_CR9","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.contraception.2015.01.007","volume":"91","author":"K Heinemann","year":"2015","unstructured":"Heinemann K, Reed S, Moehner S, Minh TD. Risk of uterine perforation with levonorgestrel-releasing and copper intrauterine devices in the European active surveillance study on intrauterine devices. Contraception. 2015;91(4):274\u20139. https:\/\/doi.org\/10.1016\/j.contraception.2015.01.007.","journal-title":"Contraception"},{"issue":"4","key":"353_CR10","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.contraception.2015.01.011","volume":"91","author":"K Heinemann","year":"2015","unstructured":"Heinemann K, Reed S, Moehner S, Minh TD. Comparative contraceptive effectiveness of levonorgestrel-releasing and copper intrauterine devices: the European active surveillance study for intrauterine devices. Contraception. 2015;91(4):280\u20133. https:\/\/doi.org\/10.1016\/j.contraception.2015.01.011.","journal-title":"Contraception"},{"issue":"4","key":"353_CR11","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1136\/jfprhc-2012-100486","volume":"39","author":"H Akintomide","year":"2013","unstructured":"Akintomide H, Sewell RDE, Stephenson JM. The use of local anaesthesia for intrauterine device insertion by health professionals in the UK. J Family Plann Reproductive Health Care. 2013;39(4):276\u201380. https:\/\/doi.org\/10.1136\/jfprhc-2012-100486.","journal-title":"J Family Plann Reproductive Health Care"},{"key":"353_CR12","doi-asserted-by":"publisher","first-page":"109997","DOI":"10.1016\/j.contraception.2023.109997","volume":"122","author":"FCQS Anjos","year":"2023","unstructured":"Anjos FCQS, Marcelino AC, Espejo-Arce X, Da Pereira PC, Barbosa PF, Juliato CT, et al. Pain and ease of insertion of three different intrauterine devices in Brazilian adolescents: A participant-blinded randomized trial. Contraception. 2023;122:109997. https:\/\/doi.org\/10.1016\/j.contraception.2023.109997.","journal-title":"Contraception"},{"issue":"45","key":"353_CR13","doi-asserted-by":"publisher","first-page":"764","DOI":"10.3238\/arztebl.2019.0764","volume":"116","author":"T R\u00f6mer","year":"2019","unstructured":"R\u00f6mer T. Medical eligibility for contraception in women at increased risk. Deutsches Arzteblatt Int. 2019;116(45):764\u201374. https:\/\/doi.org\/10.3238\/arztebl.2019.0764.","journal-title":"Deutsches Arzteblatt Int"},{"key":"353_CR14","unstructured":"World Health Organization. Medical Eligibility Criteria for Contraceptive Use. 5th ed. Geneva; 2015."},{"issue":"1","key":"353_CR15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.53260\/EGO.224015","volume":"4","author":"T Boehnke","year":"2022","unstructured":"Boehnke T, Bauerfeind A, Hagemann C, Lange JA, Heinemann K. Intrauterine device prescribing patterns and types in Europe \u2013 a cross-sectional analysis of the European active surveillance LCS12 study. Eur Gynecol Obstet. 2022;4(1):29\u201340. https:\/\/doi.org\/10.53260\/EGO.224015.","journal-title":"Eur Gynecol Obstet"},{"key":"353_CR16","volume-title":"Report 2022","author":"HHP Kluge","year":"2022","unstructured":"Kluge HHP, WHO European Regional Obesity. Report 2022. Copenhagen: World Health Organization, Regional Office for Europe; 2022."},{"issue":"5","key":"353_CR17","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/0010-7824(95)00210-2","volume":"52","author":"T Luukkainen","year":"1995","unstructured":"Luukkainen T, Toivonen J. Levonorgestrel-releasing IUD as a method of contraception with therapeutic properties. Contraception. 1995;52(5):269\u201376. https:\/\/doi.org\/10.1016\/0010-7824(95)00210-2.","journal-title":"Contraception"},{"issue":"7","key":"353_CR18","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1080\/14656566.2018.1462337","volume":"19","author":"G Grandi","year":"2018","unstructured":"Grandi G, Farulla A, Sileo FG, Facchinetti F. Levonorgestrel-releasing intra-uterine systems as female contraceptives. Expert Opin Pharmacother. 2018;19(7):677\u201386. https:\/\/doi.org\/10.1080\/14656566.2018.1462337.","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"353_CR19","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1097\/OGX.0000000000000155","volume":"70","author":"J Bitzer","year":"2015","unstructured":"Bitzer J, Heikinheimo O, Nelson AL, Calaf-Alsina J, Fraser IS. Medical management of heavy menstrual bleeding: a comprehensive review of the literature. Obstet Gynecol Surv. 2015;70(2):115\u201330. https:\/\/doi.org\/10.1097\/OGX.0000000000000155.","journal-title":"Obstet Gynecol Surv"},{"key":"353_CR20","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2147\/ijwh.s4350","volume":"1","author":"PH Bednarek","year":"2010","unstructured":"Bednarek PH, Jensen JT. Safety, efficacy and patient acceptability of the contraceptive and non-contraceptive uses of the LNG-IUS. Int J Womens Health. 2010;1:45\u201358. https:\/\/doi.org\/10.2147\/ijwh.s4350.","journal-title":"Int J Womens Health"},{"issue":"2","key":"353_CR21","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1002\/ijgo.13716","volume":"156","author":"M Laporte","year":"2022","unstructured":"Laporte M, Metelus S, Ali M, Bahamondes L. Major differences in the characteristics of users of the copper intrauterine device or levonorgestrel intrauterine system at a clinic in Campinas, Brazil. Int J Gynaecol Obstet. 2022;156(2):240\u20136. https:\/\/doi.org\/10.1002\/ijgo.13716.","journal-title":"Int J Gynaecol Obstet"},{"issue":"5","key":"353_CR22","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1055\/s-0031-1287662","volume":"29","author":"IS Fraser","year":"2011","unstructured":"Fraser IS, Critchley HOD, Broder M, Munro MG. The FIGO recommendations on terminologies and definitions for normal and abnormal uterine bleeding. Semin Reprod Med. 2011;29(5):383\u201390. https:\/\/doi.org\/10.1055\/s-0031-1287662.","journal-title":"Semin Reprod Med"},{"issue":"2","key":"353_CR23","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/0010-7824(88)90035-2","volume":"38","author":"EM Belsey","year":"1988","unstructured":"Belsey EM, Farley TM. The analysis of menstrual bleeding patterns: a review. Contraception. 1988;38(2):129\u201356. https:\/\/doi.org\/10.1016\/0010-7824(88)90035-2.","journal-title":"Contraception"},{"issue":"4","key":"353_CR24","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1080\/13625187.2018.1483018","volume":"23","author":"AL Lunardi Rocha","year":"2018","unstructured":"Lunardi Rocha AL, Cristina Fran\u00e7a Ferreira M, Mara Lamaita R, Batista C\u00e2ndido E, Mendon\u00e7a Carneiro M, Da Silva-Filho L. Heavy menstrual bleeding: a global survey of health care practitioners\u2019 perceptions. Eur J Contracept Reprod Health Care. 2018;23(4):288\u201394. https:\/\/doi.org\/10.1080\/13625187.2018.1483018.","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"3","key":"353_CR25","doi-asserted-by":"publisher","first-page":"242","DOI":"10.3109\/13625187.2016.1154144","volume":"21","author":"RE Nappi","year":"2016","unstructured":"Nappi RE, Fiala C, Chabbert-Buffet N, H\u00e4usler G, Jamin C, Lete I, et al. Women\u2019s preferences for menstrual bleeding frequency: results of the inconvenience due to women\u2019s monthly bleeding (ISY) survey. Eur J Contracept Reprod Health Care. 2016;21(3):242\u201350. https:\/\/doi.org\/10.3109\/13625187.2016.1154144.","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"4","key":"353_CR26","doi-asserted-by":"publisher","first-page":"270","DOI":"10.3109\/13625187.2012.684811","volume":"17","author":"A Szarewski","year":"2012","unstructured":"Szarewski A, von Stenglin A, Rybowski S. Women\u2019s attitudes towards monthly bleeding: results of a global population-based survey. Eur J Contracept Reprod Health Care. 2012;17(4):270\u201383. https:\/\/doi.org\/10.3109\/13625187.2012.684811.","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"4","key":"353_CR27","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1080\/13625187.2017.1334258","volume":"22","author":"C Fiala","year":"2017","unstructured":"Fiala C, Chabbert-Buffet N, H\u00e4usler G, Jamin C, Lete I, Lobo P, et al. Women\u2019s preferences for menstrual bleeding frequency in 12 European countries: the inconvenience due to women\u2019s monthly bleeding (ISY) survey. Eur J Contracept Reprod Health Care. 2017;22(4):268\u201373. https:\/\/doi.org\/10.1080\/13625187.2017.1334258.","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"1","key":"353_CR28","doi-asserted-by":"publisher","first-page":"8","DOI":"10.4103\/0976-7800.109627","volume":"4","author":"N Magon","year":"2013","unstructured":"Magon N, Chauhan M, Goel P, Malik S, Kapur K, Kriplani A, et al. Levonorgestrel intrauterine system: current role in management of heavy menstrual bleeding. J Midlife Health. 2013;4(1):8\u201315. https:\/\/doi.org\/10.4103\/0976-7800.109627.","journal-title":"J Midlife Health"},{"key":"353_CR29","doi-asserted-by":"publisher","unstructured":"World Medical Association Declaration of Helsinki. JAMA. 2013;310(20):2191\u20134. https:\/\/doi.org\/10.1001\/jama.2013.281053.: ethical principles for medical research involving human subjects.","DOI":"10.1001\/jama.2013.281053"},{"issue":"1","key":"353_CR30","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/pds.3891","volume":"25","author":"International Society of Pharmacoepidemiology","year":"2016","unstructured":"International Society of Pharmacoepidemiology. Guidelines for good pharmacoepidemiology practice (GPP). Pharmacoepidemiol Drug Saf. 2016;25(1):2\u201310. https:\/\/doi.org\/10.1002\/pds.3891.","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Contraception and Reproductive Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40834-025-00353-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40834-025-00353-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40834-025-00353-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T04:52:45Z","timestamp":1741927965000},"score":1,"resource":{"primary":{"URL":"https:\/\/contraceptionmedicine.biomedcentral.com\/articles\/10.1186\/s40834-025-00353-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,14]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["353"],"URL":"https:\/\/doi.org\/10.1186\/s40834-025-00353-8","relation":{},"ISSN":["2055-7426"],"issn-type":[{"value":"2055-7426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,14]]},"assertion":[{"value":"23 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"EURAS-LCS12 was approved by the relevant Independent Ethics Committee (IEC)\/Institutional Review Board (IRB) and was conducted in compliance with the IEC\/IRB, informed consent regulations, the declaration of Helsinki [], and the Good Epidemiological Practice (GEP)\/ Good pharmacovigilance practices (GVP)\/ Good Pharmacoepidemiology Practice (GPP) guidelines []. Written informed consent for use of a participant\u2019s sensitive data was obtained from the participant, or their legally acceptable representative, before entry into the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20"}}